After Biogen indicated that it could be considering a sale of its biosimilars business, Korean media reports have pointed to Samsung Bioepis as a potential buyer. However, responding to the rumors in comments to Generics Bulletin, Samsung Bioepis declined to confirm that a deal was in the offing.
Biogen has made it clear for some time that it is considering selling its biosimilars business to a new owner, as part of a strategic review of the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?